Clinical Trial Detail

NCT ID NCT02912572
Title Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

endometrial cancer

Therapies

Avelumab + Talazoparib

Avelumab

Avelumab + Axitinib

Age Groups: senior adult

Additional content available in CKB BOOST